Trump’s claim of world’s lowest drug prices is misleading

The CEA describes the policy’s goal as narrowing the international gap through both US price cuts and higher prices in other wealthy countries. A smaller gap therefore need not result from American price reductions alone. [2]

On 18 September, the White House said it had agreements with 26 manufacturers covering 89% of the branded drug market. That figure describes the companies’ market presence, not the proportion of prescriptions already purchased at MFN rates. The administration also reported more than $700 million in savings through TrumpRx since its February launch and forecast about $600 billion in savings over ten years. [9]

What price comparisons show

The historical US price problem was real. RAND’s comparison using 2022 data found gross US prices for original brand-name medicines were 4.22 times prices in peer countries. Even after an estimated adjustment for US manufacturer rebates, they remained more than three times as high. Unbranded generics were already cheaper than in most peers, but original branded medicines accounted for 87% of US drug spending at gross manufacturer prices. [5]

A Peterson-KFF Health System Tracker analysis published on 24 September 2026 compared 32 TrumpRx brand-name products without US generic or biosimilar competition. It used prices listed on TrumpRx on 25 August and foreign public prices from up to 11 wealthy countries. Five products were cheapest in their respective comparisons; 13 were the most expensive. Still, 17 were below the average of available peer-country prices and 15 above it. [4]

This was a selected August snapshot, not a national price index or a test of changes caused by the agreements. Foreign public prices do not always represent a patient’s bill, and the study made no purchasing-power adjustment. It also found German prices higher for 14 of 24 matched products. [4]

Trump’s percentages involve a separate distinction. The post calls them “Price Differences”, not percentage reductions. A price 700% higher than another is eight times as high; cutting it to the lower price would be an 87.5% reduction. That arithmetic is possible, but the post gives no prices or basis of comparison from which to calculate his figures. [1]

Ozempic illustrates how specific a cash offer can be. On 20 October, TrumpRx advertised $199 for each of the first two monthly fills for eligible new self-paying patients using 0.25mg or 0.5mg doses. The introductory offer is available until 31 December 2026. Subsequent monthly prices are listed at $349 for 0.25mg, 0.5mg or 1mg, and $499 for 2mg. [6]

The page warns that insurance co-payments may be lower and that purchases under the offer do not count towards an insurance deductible or out-of-pocket limit. Specific offers can be valuable to eligible patients; they do not establish that Americans as a whole now pay the world’s lowest drug prices. [6] [2]